Full-Time
Posted on 7/16/2026
Pharmaceutical company developing medicines and vaccines
$117k - $184.2k/yr
North Wales, PA, USA + 1 more
More locations: Linden, NJ, USA
Hybrid
Hybrid role with on-site days at North Wales, PA and Rahway, NJ.
Master's, PhD
See people who can refer or advise you
Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kenilworth, Illinois
Founded
1891
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Hybrid Work Options
Merck raised its 2026 revenue forecast to between $66.3 billion and $67.3 billion, up from a previous range of $65.8 billion to $67 billion. However, the company cut its adjusted earnings outlook to $2.66 to $2.76 per share, down from $5.04 to $5.16, due to one-time charges totalling $14.7 billion related to acquisitions of Terns and Cidara Therapeutics. For the second quarter, Merck reported $16.61 billion in revenue, up 5% year-over-year. Keytruda generated $8.37 billion in sales, whilst newer drugs showed strong growth. Winrevair sales reached $588 million, up 75%, and Capvaxive posted $184 million, up 42%. The company is acquiring businesses to offset upcoming generic competition for several drugs, including Keytruda in 2028.
Merck (MRK) earnings Q2 2026. Merck & Co. announced strong second-quarter results while updating its revenue outlook as new products have demonstrated significant growth. The pharmaceutical company raised its 2026 revenue forecast to between $66.3 billion and $67.3 billion, up from a prior range of $65.8 billion to $67 billion. However, Merck lowered its profit guidance following a $5.7 billion charge related to its acquisition of Terns Pharmaceuticals. The projected adjusted earnings per share are now expected to be between $2.66 and $2.76, reflecting this one-time charge and a $9 billion impairment linked to the acquisition of Cidara Therapeutics earlier this year. This adjustment brings the previous earnings estimate down from a range of $5.04 to $5.16 per share. Merck's net loss for the quarter amounted to $1.34 billion, equivalent to 54 cents per share, compared to a net income of $4.43 billion, or $1.76 per share, during the same period last year. Notably, revenue for the quarter reached $16.61 billion, marking a 5% increase year-over-year. Sales of the immunotherapy drug Keytruda were noteworthy, generating $8.37 billion in the second quarter, which exceeded analyst expectations. Additionally, Merck's newer products, including Winrevair and the pneumococcal vaccine Capvaxive, showed promising sales growth. Merck's animal health division also performed well, generating $1.78 billion in sales, which surpassed estimates. Why this story matters Key takeaway Opposing viewpoint
Merck is set to announce its Q2 earnings on Tuesday before market hours. The market expects revenue to grow 3% year-on-year, reversing the 1.9% decrease recorded in the same quarter last year. Last quarter, Merck reported revenues of $16.29 billion, up 4.9% year-on-year, beating analysts' expectations. The company also exceeded EPS estimates. Analysts have generally reconfirmed their estimates over the last 30 days. Among peers, Corcept reported 7.3% revenue growth but missed estimates by 1%, whilst Bristol-Myers Squibb posted 5.7% growth, topping estimates by 12.9%. Merck's share price has risen 2.6% over the past month, with an average analyst price target of $135.19 compared to the current share price of $130.31.
StockStory analysed three cash-producing stocks, recommending investors avoid two while highlighting one with stronger prospects. Allegro MicroSystems faces end-market challenges, with flat sales over two years and operating margin falling to 2% over five years. The power management chip designer trades at 37.6x forward P/E. Viavi Solutions showed weak performance with 3.4% annual growth over five years, whilst earnings per share remained flat despite revenue growth. The telecommunications testing company trades at 26.2x forward P/E. Merck emerged as the recommended stock, boasting a 21.5% trailing 12-month free cash flow margin. The pharmaceutical company's portfolio includes the blockbuster cancer immunotherapy Keytruda. The analysis emphasises that strong cash flow alone doesn't guarantee superior returns without efficient capital allocation.
Singapore group will develop 'most promising' Ebola vaccine. The Singapore-based Hilleman Laboratories announced it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. 30 Jul 2026 06:31PM (Updated: 30 Jul 2026 06:36PM) Add CNA as a trusted source to help Google better understand and surface our content in search results. Read a summary of this article on FAST. PARIS: A Singapore-based organisation announced on Thursday (Jul 30) it will develop an Ebola vaccine dubbed the "most promising" to fight back against a deadly outbreak in the Democratic Republic of Congo. Nearly 1,500 people have died in the conflict-wracked African country from the Bundibugyo strain of Ebola, for which there are no vaccines or treatments. But there are several different efforts racing to develop a vaccine for the previously rare strain in the hope of stemming the escalating outbreak. World Health Organization experts have said a single-dose shot based on the rVSV platform is the "most promising" candidate. This is because it uses the same platform as the only officially licensed Ebola vaccine Ervebo, which targets a different strain called Zaire. The Singapore-based Hilleman Laboratories announced on Thursday it would advance the rVSV Bundibugyo jab so it can be tested on humans during clinical trials. The organisation is a joint venture between the US pharma giant MSD - known as Merck in North America - and the British charity Wellcome Trust. "We're racing to develop a Bundibugyo vaccine and make doses for clinical trials," Hilleman Laboratories CEO Raman Rao said in a statement. MSD developed and manufactured Ervebo and "will serve as a technical adviser" providing "expertise on the rVSV platform", the statement added. It was a joint statement with the Coalition for Epidemic Preparedness Innovations (CEPI), which has pledged funds to the rVSV shot and other Ebola vaccine efforts. If early trials are successful and the vaccine is authorised, CEPI and Hilleman said they hoped to "ensure rapid, affordable supply of doses in outbreak-affected countries and low- and middle-income settings". The Ervebo vaccine needs to be stored at ultra-low temperatures. However, the new Bundibugyo jab is hoped to last for months in normal refrigerators, making it cheaper and easier to deploy to remote areas. In May, WHO experts cautioned it would likely take seven to nine months before the rVSV vaccine is ready to be assessed in a clinical trial. The vaccine uses a modified version of the vesicular stomatitis virus, an animal virus, as a vector to deliver a protein from the Bundibugyo ebolavirus to the human immune system, triggering an immune response. The announcement comes a week after the first dose of a different Bundibugyo vaccine being developed by Oxford University was injected into a volunteer during a rapidly launched clinical trial. The epidemic in DR Congo is now the third-largest Ebola outbreak on record. There have been 3,360 confirmed cases, including 1,487 deaths since May, with the outbreak heavily centred on the northeastern Ituri province. Uganda, which borders Ituri, has seen 20 confirmed cases, including two confirmed deaths. A viral haemorrhagic fever, Ebola spreads through close contact and infected bodily fluids. Related topics.